February 14, 2025
UNC Lineberger has opened a two-arm clinical trial to determine the optimal combination treatment for patients with advanced unresectable or metastatic basal-like subtype pancreatic ductal adenocarcinoma.
January 28, 2025
The nation’s top gastrointestinal cancer clinical translational researchers convened in Chapel Hill for the 2025 GI SPORE Investigators Meeting.
December 9, 2024
Researchers in the lab of Jen Jen Yeh, MD, have identified two kinotypes that differentiate the two established molecular subtypes pancreatic cancer, as reported in a paper published in Cancer Discovery.
November 21, 2024
Nurse navigators and nurse practitioners are crucial members of our team at the N.C. Basnight Cancer Hospital, UNC Lineberger’s clinical home.
October 15, 2024
The NIH has awarded a five-year, $2.79 million R01 research grant to Justin Milner, PhD, to define how a druggable family of epigenetic regulators control T cell activity.
September 23, 2024
Naim Rashid, PhD, has received a Department of Defense Pancreatic Cancer Research Program pilot award to build an AI tool that generates personalized clinical trial recommendations for patients with PDAC.
August 6, 2024
A phase I gene therapy study at UNC Lineberger is now recruiting patients with refractory pancreatic ductal adenocarcinoma (PDAC) to test the safety and tolerability of escalating doses of iC9.CAR.B7-H3 T-cells.
June 6, 2024
UNC Lineberger researchers have established the most comprehensive molecular portrait of the workings of KRAS, a key cancer-causing gene, and how its activities impact pancreatic cancer outcomes.
June 6, 2024
March 4, 2024
The grant will support the first metastatic pancreatic cancer trial in the country to evaluate whether selecting treatment by tumor subtype will help patients match to more effective first-line therapies.
